IL1B and congenital rubella syndrome: An alternate strategy for treating CRS in COVID-19 are also biologic agents including anti-IL-6Rα (tocilizumab and sarilumab), anti-IL-1 (anakinra), anti-CD20 (rituximab) and anti-GM-CSF (mavrilimumab, lenzilumab, gimsilumab); however, to evaluate the efficacy of these therapeutic modalities are still ongoing.